Tom Skelton to Step Down in December 2022 After More Than Seven Years at Helm; Company Initiates Search for Successor
ARLINGTON, Va.–(BUSINESS WIRE)–#healthIT—Surescripts, the nation’s leading health information network, today announced that Chief Executive Officer Tom Skelton has informed the Board of his decision to step down from his position at Surescripts to retire, effective December 31, 2022. Skelton will continue to lead Surescripts for the next year and will be an active participant with the Board in the search for his successor. He is also committed to working with the new CEO through a transition period to ensure a seamless transfer of leadership.
“As Tom prepares for his well-deserved retirement, we celebrate the many accomplishments Surescripts has achieved under his leadership these past seven years,” said Dr. Steve Miller, Surescripts Board Co-Chair and Chief Clinical Officer, Cigna.
Under Skelton’s tenure, Surescripts launched some of its most innovative solutions including Real-Time Prescription Benefit, which now has more than 550,000 prescribers using it in their electronic health record to access benefits-based prescription price information at the point of prescribing. The company also focused on improving the accuracy of electronic prescriptions, increasing the efficiency and simplicity of sharing health intelligence to improve care. Surescripts was named one of Modern Healthcare’s Best Places to Work in Healthcare in 2020 and 2021.
“We are pleased with Tom’s commitment to maintaining the same high level of engagement he has demonstrated throughout his successful Surescripts tenure and the Board looks forward to working with Tom on the search for a successor and on a smooth leadership transition,” said Douglas Hoey, Surescripts Board Co-Chair and Chief Executive Officer of the National Community Pharmacists Association.
“Being CEO of Surescripts has been a highlight of my career. I’ve been fortunate to have the opportunity to work with a team of professionals who share a passion for our purpose – to lower costs, improve quality and increase safety,” explained Skelton. “My role as CEO is one that I have loved and my team inspires me every day. As much as I love Surescripts, it is now time for me to pursue my other interests and spend more time with my family. Surescripts is positioned for a bright future and I am committed to making the transition to a new CEO smooth.”
About Surescripts
Our purpose is to serve the nation with the single most trusted and capable health information network, built to increase patient safety, lower costs and ensure quality care. Since 2001, Surescripts has led the movement to turn data into actionable intelligence, and convened the Surescripts Network Alliance® to enhance prescribing, inform care decisions and advance the healthcare industry. Visit us at surescripts.com and follow us at twitter.com/surescripts.
Contacts
Nora Langan
Surescripts
(215) 565-5790
nora.langan@surescripts.com
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
